Entia Liberty: Home Study

Entia

Status: Completed

Conditions: Cancer

Treatments: Device: Entia Liberty

Study type: Observational

Funder types: Industry

Identifiers

NCT05462288

317614

Details and patient eligibility

About

Participants will be testing with the home monitoring device over the course of their treatment. They are to self-test on days where they are due to be going into hospital for their routine pre-treatment blood tests. Participants will be asked to fill in interim questionnaires and a final questionnaire to answer the study objectives.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18
• Adequate English language skills (not requiring a translator) to participate in participant training and use the Liberty device
• Patients willing and able to perform capillary blood self-testing at the same frequency as routine full blood count monitoring
• Patients capable of providing informed consent before attending training
• Patients able to attend a 1-hour virtual training session within 2 weeks of joining the study
• Patients with a home Wi-Fi network or with adequate coverage at home via a 4G network
• Patients with access to a laptop or smartphone to facilitate training
• Patients with a diagnosis of ovarian or breast cancer
• Patients whose HCPs can confirm are undergoing systemic anti-cancer treatments within two weeks of enrolment, with treatment expected to continue for at least two cycles

Exclusion criteria

• Patients with haematological malignancies
• Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Liberty device or participation in training unless they have a nominated caregiver who is capable of assisting with each test

Trial design

22 participants in 1 patient group

Patient Group

Treatment:

Device: Entia Liberty